Get 30% off on all global market reports with code ONLINE30 – stay updated on tariff changes, macroeconomic trends, and more!
Growth Hormone Deficiency Market Size Expansion: A Snapshot of Growth Between 2024 and 2029
The market for growth hormone deficiency has seen a substantial rise in recent times. The market value that was $4.06 billion in 2024 will see a significant increase to $4.3 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 5.8%. This upswing witnessed in the historical period can be attributed to several factors such as a rise in strategic initiatives, an increase in the incidents of brain tumors, an escalating demand for hormone therapies, an increased population of the elderly, and the government allocating more funds for healthcare.
The market size for growth hormone deficiency is anticipated to experience robust growth in the coming years, projected to reach $5.38 billion by 2029 with a compound annual growth rate (CAGR) of 5.7%. The expected growth during the forecast period can be attributed to factors such as an increasing occurrence of genetic disorders, a rise in strategic initiatives, enhanced research and development, growing Gh disease morbidity, and an increase in the number of clinical trials. The forecast period is also expected to witness major trends such as technological innovation, an array of new treatment options, breakthroughs in diagnostic techniques, recent developments, and progress in biotechnology.
Claim Your Free Sample Report:
http://www.thebusinessresearchcompany.com/sample….p;type=smp
What’s Driving the Continued Growth of the Global Growth Hormone Deficiency Market?
The increase in instances of genetic disorders is anticipated to drive the expansion of the growth hormone deficiency market. Genetic disorders, which can be either inherited or develop spontaneously, are health issues caused by abnormalities or mutations in a person’s DNA. The rise in such disorders can be attributed to advancements in diagnostic technology, heightened awareness, an increase in maternal age, environmental elements leading to mutations, population increase, and improved survival rates for those affected. Growth hormone deficiency treatments are employed to manage growth-related issues in certain genetic conditions. As an example, a report from the Department of Health & Social Care (DHSC), a government department based in the UK, revealed that around 33,000 whole genome equivalents were sequenced in October 2022, and the average diagnostic yield stood at 32% which rose to 61% in specific cases. This rise in genetic disorders, therefore, propels the growth of the growth hormone deficiency market.
Top Revenue-Generating Segments in the Growth Hormone Deficiency Market
The growth hormone deficiencymarket covered in this report is segmented –
1) By Type: Pediatric Growth Hormone Deficiency; Adult Growth Hormone Deficiency
2) By Treatment: Pharmacological Therapy; Recombinant Human Growth Hormone; Human Pituitary Gland Extracts; Surgery
3) By Route Of Administration: Intravenous; Intramuscular; Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
Subsegments:
1) By Pediatric Growth Hormone Deficiency: Idiopathic Growth Hormone Deficiency; Genetic Growth Hormone Deficiency; Acquired Growth Hormone Deficiency
2) By Adult Growth Hormone Deficiency: Primary Growth Hormone Deficiency; Secondary Growth Hormone Deficiency
Access the Full Report Today:
http://www.thebusinessresearchcompany.com/report/…ket-report
Which Trends Will Guide the Development Path of the Growth Hormone Deficiency Industry?
Key players in the growth hormone deficiency market are shifting their focus towards pioneering product developments such as the unmodified somatropin for daily pediatric growth hormone deficiency (GHD) treatments.
Unmodified somatropin denotes the same growth hormone used in daily pediatric GHD treatments, but Skytrofa delivers it in a once-a-week dose. For example, in September 2023, Ascendis Pharma A/S, a biopharmaceutical company from Denmark, introduced SKYTROFA (lonapegsomatropin) as a weekly treatment of pediatric growth hormone deficiency (GHD). This inventive therapy promises superior convenience, better adherence, and potentially superior treatment results compared to conventional daily growth hormone therapies. This trailblazing progression in endocrinology and pediatric care is the first and only FDA-validated once-a-week treatment for pediatric GHD.
How Are Different Regions Contributing to the Growth Hormone Deficiency Market’s Growth?
North America was the largest region in the growth hormone deficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the growth hormone deficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get a Customized Version of the Report:
http://www.thebusinessresearchcompany.com/customi…p;type=smp
Which Firms Are Setting the Benchmark in the Global Growth Hormone Deficiency Market?
Major companies operating in the growth hormone deficiency market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Eli Lilly and Company, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Genentech Inc., Ipsen Biopharmaceuticals Inc., Opko Health Inc., JCR Pharmaceuticals Co. Ltd., Ferring Pharmaceuticals Inc., Ascendis Pharma A/S, Rani Therapeutics Inc., AnkeBio Co. Ltd., Aeterna Zentaris Inc., Zhongshan Sinobioway Hygene Biomedicine Co. Ltd., Versartis Inc., I-Mab Biopharma Co. Ltd.
Access the Complete Report:
http://www.thebusinessresearchcompany.com/purchas…x?id=21197
How Our Market Research Reports Help Maximize ROI Across Industries:
* Identify High-Growth Opportunities: Pinpoint emerging trends, untapped segments, and regional hotspots that align with your strategic goals.
* Reduce Investment Risk: Make data-driven decisions with confidence by understanding market dynamics, key drivers, and competitive threats.
* Optimize Strategic Planning: Align your product development, marketing, and expansion plans with industry forecasts and customer behaviour insights.
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
News From
The Business Research Company …
Category: Industry Reports & Market Analysis Profile: The Business Research Company is a leading market research and consulting services provider. It offers over 9,500 market reports across 27 industries in 60+ geographies, providing detailed insights and forecasts. Its customised research solutions support companies in making critical decisions, while its continuous research service enhances organizational capabilities. The flagship Global Market Model database provides comprehensive market intelligence with 1,500,000 datasets covering 8,000+ mark …
This email address is being protected from spambots. You need JavaScript enabled to view it.
